Inventor · disambiguated record
John M. Yanni
Also filed as: NAKAKURA MASASHI · YANNI JOHN · YANNI JOHN M
57 granted patents·44 pending applications·1,461 citations·filing 1985–2021
99Inventor score
Top patents by PatentIndex Score
101 records- 0197US4950674AArylalkylheterocyclic amines,N-substituted by aryloxyalkyl group in a method for allergy treatmentROBINS CO INC A H·Filed 1988·Granted Aug 21, 1990·68 cites·57 claims
- 0296US4810713AArylalkyl-heterocyclic amines, n-substituted by aryloxyalkyl groups used in a method for allergy treatmentROBINS CO INC A H·Filed 1985·Granted Mar 7, 1989·54 cites·101 claims
- 0395US6872382B1Use of selective PDE IV inhibitors to treat dry eye disordersALCON INC·Filed 2002·Granted Mar 29, 2005·64 cites·4 claims
- 0495US6740664B2Methods for treating otic and ophthalmic infectionsALCON INC·Filed 2001·Granted May 25, 2004·96 cites·18 claims
- 0595US6716830B2Ophthalmic antibiotic compositions containing moxifloxacinALCON INC·Filed 2002·Granted Apr 6, 2004·47 cites·14 claims
- 0695US6509327B1Compositions and methods for treating otic, ophthalmic and nasal infectionsALCON MFG LTD·Filed 2000·Granted Jan 21, 2003·81 cites·5 claims
- 0793US6420399B1Topical ophthalmic mast cell stabilizers for treating allergic eye diseaseALCON MFG LTD·Filed 2000·Granted Jul 16, 2002·57 cites·2 claims
- 0892US6645978B1Lipoxin A4 and its analogs for the treatment of dry eyeALCON INC·Filed 2000·Granted Nov 11, 2003·39 cites·5 claims
- 0992US6440964B1Compositions and methods for treating ophthalmic and otic infectionsALCON MFG LTD·Filed 2001·Granted Aug 27, 2002·50 cites·6 claims
- 1090US6395746B1Methods of treating ophthalmic, otic and nasal infections and attendant inflammationALCON MFG LTD·Filed 1999·Granted May 28, 2002·103 cites·11 claims
- 1190US6353022B1Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disordersALCON UNIVERSAL LTD·Filed 2000·Granted Mar 5, 2002·38 cites·22 claims
- 1289US5696166ACompositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disordersFiled 1995·Granted Dec 9, 1997·93 cites·7 claims
- 1388US8993636B2Compositions containing moxifloxacin for treating otic infectionsALCON INC·Filed 2013·Granted Mar 31, 2015·3 cites·12 claims
- 1488US6649602B1Use of an H1 antagonist and a safe steroid to treat eye conditionsALCON INC·Filed 2000·Granted Nov 18, 2003·30 cites·9 claims
- 1588US5811453AViscoelastic compositions and methods of useALCON LAB INC·Filed 1996·Granted Sep 22, 1998·70 cites·16 claims
- 1688US5475034ATopically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disordersALCON LAB INC·Filed 1994·Granted Dec 12, 1995·69 cites·7 claims
- 1786US8222227B2RNAi-mediated inhibition of histamine receptor H1-related conditionsYANNI JOHN M·Filed 2011·Granted Jul 17, 2012·6 cites·13 claims
- 1886US6174878B1Topical use of kappa opioid agonists to treat otic painALCON LAB INC·Filed 1999·Granted Jan 16, 2001·71 cites·15 claims
- 1985US8017592B2RNAi-mediated inhibition of histamine receptor H1-related conditionsALCON RES LTD·Filed 2007·Granted Sep 13, 2011·5 cites·13 claims
- 2085US5624893APharmaceutical compositions and methods of treatment of the cornea following laser irradiationALCON LAB INC·Filed 1994·Granted Apr 29, 1997·75 cites·15 claims
- 2184US7732421B2RNAI-mediated inhibition of tumor necrosis factor α-related conditionsALCON RES LTD·Filed 2007·Granted Jun 8, 2010·4 cites·12 claims
- 2284US6375973B2Ophthalmic anti-allergy compositions suitable for use with contact lensesALCON UNIVERSAL LTD·Filed 2001·Granted Apr 23, 2002·18 cites·19 claims
- 2382US8048863B2RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditionsALCON RES LTD·Filed 2007·Granted Nov 1, 2011·3 cites·36 claims
- 2482US7671070B2Method of treating ophthalmic infections with moxifloxacin compositionsALCON INC·Filed 2003·Granted Mar 2, 2010·8 cites·42 claims
- 2582US6429227B1Hydroxyeicosatetraenoate salts, compositions and methods of use in treating dry eye disordersALCON UNIVERSAL LTD·Filed 2000·Granted Aug 6, 2002·20 cites·29 claims
- 2681US8138205B2Heteroarylalkoxy-substituted quinolone inhibitors of PDE4GOVEK STEVEN P·Filed 2009·Granted Mar 20, 2012·4 cites·19 claims
- 2781US5641805ATopical ophthalmic formulations for treating allergic eye diseasesALCON LAB INC·Filed 1995·Granted Jun 24, 1997·51 cites·12 claims
- 2880US9453220B2RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disordersARROWHEAD RES CORP·Filed 2014·Granted Sep 27, 2016·2 cites·8 claims
- 2979US9206428B2RNAi-mediated inhibition of histamine receptor H1-related conditionsARROWHEAD RES CORP·Filed 2013·Granted Dec 8, 2015·2 cites·17 claims
- 3078US8618278B2RNAi-mediated inhibition of histamine receptor H1-related conditionsYANNI JOHN M·Filed 2012·Granted Dec 31, 2013·2 cites·4 claims
- 3177US8673873B1RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disordersYANNI JOHN M·Filed 2009·Granted Mar 18, 2014·1 cites·6 claims
- 3277US6638976B2Method of treating neurodegenerative disorders of the retina and optic nerve headALCON INC·Filed 2001·Granted Oct 28, 2003·10 cites·12 claims
- 3377US6242480B1Ophthalmic viscoelastic compositionsALCON LAB INC·Filed 1997·Granted Jun 5, 2001·17 cites·8 claims
- 3475US6353012B115-Hydroxyeicosatetraenoic acid-related compounds and methods of useALCON UNIVERSAL LTD·Filed 2000·Granted Mar 5, 2002·8 cites·11 claims
- 3575US5612364ASubstantially pure apraclonidineALCON LAB INC·Filed 1995·Granted Mar 18, 1997·18 cites·4 claims
- 3670US2008096852A1Use of oculosurface selective glucocorticoid in the treatment of dry eyeALCON INC·Filed 2007·Application pending·0 cites
- 3768US6646003B2Method of treating ocular inflammatory and angiogenesis-related disorders of the posterior segment of the eye using an amide derivative of flurbiprofen or ketorolacALCON INC·Filed 2002·Granted Nov 11, 2003·3 cites·8 claims
- 3867US5192780AMethods using antiallergics and antihistaminesALCON LAB INC·Filed 1991·Granted Mar 9, 1993·32 cites·4 claims
- 3967US2019032061A1RNAi-Mediated Inhibition of Tumor Necrosis Factor Alpha-Related ConditionsARROWHEAD PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 4066US9447419B2RNAi-mediated inhibition of tumor necrosis factor α-related conditionsARROWHEAD RES CORP·Filed 2014·Granted Sep 20, 2016·0 cites·12 claims
- 4166US6696453B2Use of NF-κB inhibitors to treat dry eye disordersALCON INC·Filed 2002·Granted Feb 24, 2004·2 cites·5 claims
- 4265US6225327B1Compounds which inhibit human conjunctival mast cell degranulation for treating ocular allergic-type complicationsALCON LAB INC·Filed 1997·Granted May 1, 2001·28 cites·3 claims
- 4364US9765340B2RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of CAMP-related ocular disordersARROWHEAD PHARMACEUTICALS INC·Filed 2016·Granted Sep 19, 2017·0 cites·21 claims
- 4464US6066671ATreatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amidesALCON LAB INC·Filed 1997·Granted May 23, 2000·17 cites·2 claims
- 4563US9371529B2RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditionsARROWHEAD RES CORP·Filed 2014·Granted Jun 21, 2016·0 cites·13 claims
- 4663US8673902B2Method of treating otic infections with moxifloxacin compositionsCAGLE GERALD·Filed 2009·Granted Mar 18, 2014·0 cites·9 claims
- 4763US2006058277A1Use of oculosurface selective glucocorticoid in the treatment of dry eyeYANNI JOHN M·Filed 2005·Application pending·0 cites
- 4863US2004132704A1Use of oculosurface selective glucocorticoid in the treatment of dry eyeFiled 2003·Application pending·0 cites
- 4962US2009131449A1Use of trpv1 receptor antagonists for treating dry eye and ocular painALCON RES LTD·Filed 2008·Application pending·0 cites
- 5062US2009098136A1Use of tnf receptor antagonists for treating dry eyeALCON RES LTD·Filed 2008·Application pending·0 cites
Showing the top 50 of 101 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when John M. Yanni files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →